Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study

References

• Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res. 2012;129(3):301–308. doi:10.1016/j.thromres.2011.11.022
   PubMed Web of Science ®Google Scholar
• Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res. 1999;41(3):722–730. doi:10.1016/S0008-6363(98)00229-6
   Web of Science ®Google Scholar
• Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost. 1995;74(1):224–227. doi:10.1055/s-0038-1642681
   PubMed Web of Science ®Google Scholar
• Evangelista V, Manarini S, Rotondo S, et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18. Blood. 1996;88(11):4183–4194. doi:10.1182/blood.V88.11.4183.4183
   PubMed Web of Science ®Google Scholar
• Graff J, Klinkhardt U, Schini-Kerth VB, et al. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther. 2002;300(3):952–957. doi:10.1124/jpet.300.3.952
   PubMed Web of Science ®Google Scholar
• Abedi H, Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 1995;30(4):544–556. doi:10.1016/S0008-6363(95)00092-5
   PubMed Web of Science ®Google Scholar
• Schini-Kerth VB, Bassus S, Fisslthaler B, Kirchmaier CM, Busse R. Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB. Circulation. 1997;96(11):3888–3896. doi:10.1161/01.CIR.96.11.3888
   Web of Science ®Google Scholar
• Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990;75(3):550–554. doi:10.1182/blood.V75.3.550.550
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95(10):2387–2394. doi:10.1161/01.CIR.95.10.2387
   PubMed Web of Science ®Google Scholar
• Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94(6):1239–1246. doi:10.1161/01.CIR.94.6.1239
   PubMed Web of Science ®Google Scholar
• Mathew JP, Rinder CS, Tracey JB, et al. Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;109(3):448–456. doi:10.1016/S0022-5223(95)70275-X
   Web of Science ®Google Scholar
• Gawaz MP. Das Blutplättchen: Physiologie, Pathophysiologie, Membranrezeptoren, antithrombozytäre Wirkstoffe und antithrombozytäre Therapie bei koronarer Herzerkrankung. Stuttgart [u.a.]: Thieme; 1999.
   Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Aids. 2003;17(8):1179–1193. doi:10.1097/00002030-200305230-00010
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.
   PubMed Web of Science ®Google Scholar
• Desvarieux M, Boccara F, Meynard JL, et al. Infection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapy. Aids. 2013;27(16):2603–2614. doi:10.1097/QAD.0b013e3283634819
   Web of Science ®Google Scholar
• Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM. Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. HIV Med. 2009;10(10):627–633. doi:10.1111/j.1468-1293.2009.00733.x
   Web of Science ®Google Scholar
• Falcinelli E, Francisci D, Belfiori B, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013;110(08):349–357. doi:10.1160/TH12-07-0504
   Web of Science ®Google Scholar
• Nordell AD, McKenna M, Borges AH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014;3(3):e000844. doi:10.1161/JAHA.114.000844
   PubMed Web of Science ®Google Scholar
• Westhorpe CL, Schneider HG, Dunne M, et al. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sex Health. 2014;11(6):580–582. doi:10.1071/SH14130
   Web of Science ®Google Scholar
• Lacerda HR, Falcao Mda C, de Albuquerque VM, et al. Association of inflammatory cytokines and endothelial adhesion molecules with immunological, virological, and cardiometabolic disease in HIV-infected individuals. J Interferon Cytokine Res. 2014;34(5):385–393. doi:10.1089/jir.2013.0029
   Web of Science ®Google Scholar
• Moyle G, Hardy H, Uy J, et al. Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy. Antivir Ther. 2014;19(7):693–699. doi:10.3851/IMP2778
   Web of Science ®Google Scholar
• Rasmussen TA, Tolstrup M, Melchjorsen J, et al. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis. 2011;11:267. doi:10.1186/1471-2334-11-267
   PubMed Web of Science ®Google Scholar
• Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7(9):e44454. doi:10.1371/journal.pone.0044454
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. doi:10.1371/journal.pmed.0050203
   PubMed Web of Science ®Google Scholar
• Ikeda H, Nakayama H, Oda T, et al. Neutrophil activation after percutaneous transluminal coronary angioplasty. Am Heart J. 1994;128(6):1091–1098. doi:10.1016/0002-8703(94)90738-2
   Web of Science ®Google Scholar
• Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23(1):17–25. doi:10.1161/01.ATV.0000046238.23903.FC
   PubMed Web of Science ®Google Scholar
• Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol. 2004;11(3):170–175. doi:10.1097/01.moh.0000130314.33410.d7
   Web of Science ®Google Scholar
• Baglin T. The measurement and application of thrombin generation. Br J Haematol. 2005;130(5):653–661. doi:10.1111/j.1365-2141.2005.05612.x
   Web of Science ®Google Scholar
• von Hentig N, Forster AK, Kuczka K, et al. Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors. J Antimicrob Chemother. 2008;62(5):1118–1121. doi:10.1093/jac/dkn333
   Web of Science ®Google Scholar
• Angdujar I, Collado-Diaz V, Ordem S, et al. Prothrombotic effects of abacavir in an in-vivo model. Conference on Retroviruses and Opportunistic Infections. 2017; Seattle, USA (Feb 13–16). Poster609.
   Google Scholar
• Wohl DA, Arnoczy G, Fichtenbaum CJ, et al. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014;19(2):141–147. doi:10.3851/IMP2681
   PubMed Web of Science ®Google Scholar
• Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood. 1991;78(7):1760–1769. doi:10.1182/blood.V78.7.1760.1760
   PubMed Web of Science ®Google Scholar
• Schmitz G, Rothe G, Ruf A, et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79(5):885–896. doi:10.1055/s-0037-1615088
   PubMed Web of Science ®Google Scholar
• Barbaro G. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection. Clin Ter. 2008;159(1):51–55.
   Web of Science ®Google Scholar
• McComsey GA, O’Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. Aids. 2007;21(8):921–927. doi:10.1097/QAD.0b013e328133f29c
   Web of Science ®Google Scholar
• Masia M, Padilla S, Bernal E, et al. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clin Ther. 2007;29(7):1448–1455. doi:10.1016/j.clinthera.2007.07.025
   PubMed Web of Science ®Google Scholar
• Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44(5):493–499. doi:10.1097/QAI.0b013e3180322542
   PubMed Web of Science ®Google Scholar
• Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep. 2006;3(3):126–131. doi:10.1007/BF02696656
   Google Scholar
• Barbaro G, Barbarini G. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy. 2006;52(4):161–165. doi:10.1159/000093034
   PubMed Web of Science ®Google Scholar
• Spieker LE, Karadag B, Binggeli C, Corti R. Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection. Heart Vessels. 2005;20(4):171–174. doi:10.1007/s00380-004-0790-8
   Web of Science ®Google Scholar
• Zhou H, Pandak WM, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol. 2005;68(3):690–700. doi:10.1124/mol.105.012898
   PubMed Web of Science ®Google Scholar
• Carr A. Cardiovascular risk factors in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S73–78. doi:10.1097/00126334-200309011-00011
   PubMed Web of Science ®Google Scholar
• Baker J, Sharma S, Grund B; Group ISS. The effect of ART on inflammation, coagulation, and vascular injury in START. Conference on Retroviruses and Opportunistic Infections. 2017; Seattle, USA (Feb 13–16). Poster608.
   Google Scholar
• Baker J, Sharma S, Grund B; Group ISS. Association of inflammation and coagulation with clinical risk in the START trial. Conference on Retroviruses and Opportunistic Infections. 2017; Seattle, USA (Feb 13–16). Poster623.
   Google Scholar
• Ryom L, Lunsgren J, el-Sadr W, et al. Associations between cardiovascular disease and contemporarily used protease inhibitors. Conference on Retroviruses and Opportunistic Infections. 2017; Seattle, USA (Feb 13–16). OP128LB.
   Google Scholar
• Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291–e300. doi:10.1016/S2352-3018(18)30043-2
   PubMed Web of Science ®Google Scholar